Teva Pharmaceutical Industries Limited

Abic Ltd.

Abic Biological Laboratories Ltd.

Abic Biological Laboratories Teva Ltd.

Gilad Gallili

Jacob Pitcovski

Bezalel Gutter

Amnon Michael

Norbert Frydman

Elena Fingerut

Doron Goldberg

Ziv Rei Koren

Margalit Mualem

Simcha Krispel

Esther Shmueli

Yifat Peretz

A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber capsid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.

Subunits of the adenovirus fiber protein and uses thereof as vaccines

A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber cpasid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.

The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.

Vaccine composition and method of using the same

The present invention relates to a DNA sequence comprising a nucleotide sequence encoding Hemorrhagic Enteritis virus. It is well known to the man of the art that determining the complete sequence of a virus enables the isolation and identification of the different genes contained therein, and their utilisation for different purposes such as for vaccination purposes, as potential vectors for gene delivery to be used in recombinant vaccination or for gene therapy. In addition, the sequence may be employed for diagnostic purposes wherein the disclosed sequence of any part thereof be used for the development of specific primers for Polymerase Chain Reaction processes (PCR) or as probes. The invention thus also concerns with HEV proteins encoded by the sequence of the invention or functional fragments thereof and to some of the uses of said sequences and proteins.

Hemorrhagic enteritis virus DNA sequences, proteins encoded thereby and various uses thereof

The present invention relates to a stable compacted, compressed or hard tableted vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.

Growing community of inventors

Jerusalem, Israel

Gilad Gallili